Nature Communications (Jun 2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- Jacob J. Chabon,
- Andrew D. Simmons,
- Alexander F. Lovejoy,
- Mohammad S. Esfahani,
- Aaron M. Newman,
- Henry J. Haringsma,
- David M. Kurtz,
- Henning Stehr,
- Florian Scherer,
- Chris A. Karlovich,
- Thomas C. Harding,
- Kathleen A. Durkin,
- Gregory A. Otterson,
- W. Thomas Purcell,
- D. Ross Camidge,
- Jonathan W. Goldman,
- Lecia V. Sequist,
- Zofia Piotrowska,
- Heather A. Wakelee,
- Joel W. Neal,
- Ash A. Alizadeh,
- Maximilian Diehn
Affiliations
- Jacob J. Chabon
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
- Andrew D. Simmons
- Clovis Oncology, Inc.
- Alexander F. Lovejoy
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
- Mohammad S. Esfahani
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
- Aaron M. Newman
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
- Henry J. Haringsma
- Clovis Oncology, Inc.
- David M. Kurtz
- Division of Oncology, Department of Medicine, Stanford University
- Henning Stehr
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
- Florian Scherer
- Stanford Cancer Institute, Stanford University
- Chris A. Karlovich
- Clovis Oncology, Inc.
- Thomas C. Harding
- Clovis Oncology, Inc.
- Kathleen A. Durkin
- Molecular Graphics and Computation Facility, College of Chemistry, University of California
- Gregory A. Otterson
- The Ohio State University
- W. Thomas Purcell
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
- D. Ross Camidge
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine
- Jonathan W. Goldman
- David Geffen School of Medicine, University of California, Los Angeles
- Lecia V. Sequist
- Massachusetts General Hospital & Harvard Medical School
- Zofia Piotrowska
- Massachusetts General Hospital & Harvard Medical School
- Heather A. Wakelee
- Division of Oncology, Department of Medicine, Stanford University
- Joel W. Neal
- Division of Oncology, Department of Medicine, Stanford University
- Ash A. Alizadeh
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
- Maximilian Diehn
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
- DOI
- https://doi.org/10.1038/ncomms11815
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 15
Abstract
EGFR-mutant non-small cell lung cancer is routinely treated with EGFR inhibitors, although resistance inevitably develops. Here, the authors sequence circulating tumour DNA and show that resistance to the third-generation inhibitor rociletinib is heterogeneous and recurrently involves somatic alterations of MET, EGFR, PIK3CA, ERRB2, and KRAS.
